Feedback
Settings

Settings

Goto Application

242,106 results
Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 24,211
1.WO/2020/181837METHOD FOR RESCUING INFLUENZA VIRUS AND COMPOSITION THEREFOR
WO - 17.09.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
 Appl.No PCT/CN2019/121905 Applicant ZHEJIANG SENWEI BIOPHARMACEUTICAL DEVELOPMENT CO., LTD. Inventor DAI, Dongsheng
Provided are a new method for rescuing an influenza virus and a composition therefor. The method comprises providing a host cell stably integrated with and expressing influenza virus PA, PB1, PB2 and NP genes, and introducing an influenza virus rescue system in which a stop codon is introduced into the PA, PB1, PB2 and NP genes respectively into the host cell to achieve virus rescue. The produced virus particles can be used as a live attenuated influenza vaccine, which is characterized in that, since the genes encoding the related proteins are mutated, it has no replication and proliferation ability in human and normal animal cells, and replication and proliferation can be achieved only in the host cells constructed above and it can fully stimulate the body immunity and effectively protect the body while ensuring the safety.
2.WO/2020/183047DECELLULARISED SCLEROCORNEAL LIMBUS
WO - 17.09.2020
Int.Class A61F 2/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
2Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
02Prostheses implantable into the body
14Eye parts, e.g. lenses, corneal implants; Artificial eyes
 Appl.No PCT/ES2020/070168 Applicant UNIVERSIDAD DE GRANADA Inventor CARO MAGDALENO, Manuel
The invention describes a biomimetic limbus obtained from decellularised sclerocorneal limbus, artifical fabric and composition comprising said limbus, in addition to its use in the preparation of a drug for treating limbal insufficiency or as a cell factor and/or drug release system.
3.WO/2020/186197MYOBLAST CHIMERIC CELLS (MCCS)
WO - 17.09.2020
Int.Class A61K 35/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
 Appl.No PCT/US2020/022712 Applicant DYSTROGEN THERAPEUTICS CORPORATION Inventor SIEMIONOW, Maria
The present invention relates to methods and compositions for generating and using myoblast chimeric cells (MCCs) for treating a muscle disease, such as muscular dystrophy, where the MCCs are composed of a myoblast derived from a patient with muscle disease (MD) and a myoblast from a donor without the MD (e.g., a healthy donor). In certain embodiments, cell fusion methods are performed using 2-4, or 5, times passaged myoblasts from the MD and donor subject, and/or polyethylene glycol 0.5 - 1.5 g/ml. In other embodiments, the MCCs created by fusion are passaged 1-5 times before use, and are passaged at 60-80% confluency. In further embodiments, the myoblasts and/or MCCs are tested at any stage during the process for less than 5-10% CD34 and/or CD45 expression, and/or greater than 50-70% CD56 and/or CD90 expression.
4.WO/2020/186217METHODS AND COMPOSITIONS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDER
WO - 17.09.2020
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
 Appl.No PCT/US2020/022761 Applicant CHILDREN'S HOSPITAL MEDICAL CENTER Inventor PAN, Dao
Methods for improving at least one neurological function in a subject that has or is suspected of having a neurologic lysosomal storage disorder using a rapamy cin compound. Also provided herein are treatment of such a neurologic lysosomal storage disorder with the rapamy cin compound.
5.WO/2020/186237MICROGLIAL PROGENITORS FOR REGENERATION OF FUNCTIONAL MICROGLIA IN THE CENTRAL NERVOUS SYSTEM AND THERAPEUTICS USES THEREOF
WO - 17.09.2020
Int.Class C12N 5/079
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
079Neural cells
 Appl.No PCT/US2020/022805 Applicant THE BROAD INSTITUTE, INC. Inventor ZHANG, Feng
Embodiments of the disclosure include compositions and methods for treating diseases (e.g., brain diseases) using genetic engineered cells. In some cases, the cells are engineered hematopoietic stem cells (HSCs), which are capable of engrafting to a central nervous system and differentiating to progeny cells (e.g., microglial cells).
6.WO/2020/186247COMPOSITIONS AND METHODS FOR PROMOTING ISLET VIABILITY AND ENHANCING INSULIN SECRETION
WO - 17.09.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/US2020/022822 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor LAURIE, Gordon, W.
Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.
7.WO/2020/182596DOSAGE FORM COMPRISING A POLYMERIC MATRIX
WO - 17.09.2020
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No PCT/EP2020/055810 Applicant EVONIK OPERATIONS GMBH Inventor MOERS, Christian
The invention is concerned with a dosage form, comprising a polymeric matrix, comprising one or more polymer(s) and a biologically active ingredient, wherein the polymeric matrix comprises 10 % by weight or more of the one or more polymer(s) and wherein the one or more polymer(s) are polymerized from a monomer mixture comprising the monomers (a) 70 to 95 % by weight of 2-ethylhexyl methacrylate (EHMA) and ethyl methacrylate (EMA) or 2-ethylhexyl methacrylate (EHMA) and methyl methacrylate (MMA), (b) 0 to 25 % by weight of a C2 to C6 hydroxy-alkylester of acrylic acid or methacrylic acid, (c) 2.5 to 20 % by weight of a C2 to C8 alkyl ester of acrylic acid or of methacrylic acid with a quaternary cationic group in the alkyl group.
8.WO/2020/182916BACTERIUM OF THE CHRISTENSENELLACEAE FAMILY FOR THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY DISEASES AND/OR INFLAMMATORY GASTROINTESTINAL DISEASES AND/OR CANCERS
WO - 17.09.2020
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
 Appl.No PCT/EP2020/056565 Applicant LNC THERAPEUTICS Inventor RAWADI, Georges
The invention relates to a bacterium of the Christensenellaceae family, in particular of the genusChristensenella, or a composition containing same for use in the prevention and/or treatment of chronic inflammatory diseases and/or cancers in humans or animals.
9.WO/2020/185056METHOD FOR CULTURING ALLOGENEIC IMMUNE CELL, IMMUNE CELL CULTURE OBTAINED THEREBY, AND IMMUNE CELL THERAPEUTIC AGENT COMPRISING SAME
WO - 17.09.2020
Int.Class C12N 5/0786
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0786Monocytes; Macrophages
 Appl.No PCT/KR2020/095016 Applicant SHIN, Ji Seop Inventor SHIN, Ji Seop
The present invention relates to a method for culturing natural killer cells (NK cells) applicable to immunotherapy and, more particularly, to: a method for culturing allogeneic immune cells wherein lymphocytes derived from blood from a healthy donor, but not from a patient to be administered an immune cell therapeutic, are cultured to effectively amplify and activate NK cells excellently effective for the therapy of malignant tumor; an immune cell culture obtained thereby; and an immune cell therapeutic comprising same.
10.WO/2020/185796HIGH AVIDITY WT1 T CELL RECEPTORS AND USES THEREOF
WO - 17.09.2020
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/US2020/021916 Applicant FRED HUTCHINSON CANCER RESEARCH CENTER Inventor SCHMITT, Thomas M.
The present disclosure provides T cell receptors (TCRs) and related binding proteins with high functional avidity against tumor associated antigen p37 from Wilms tumor protein 1 (WT1), T cells expressing such high affinity WT1 specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress WT1 and/or produce the p37 antigen, such as in cancer.
# -